News and Events

12/14/2011 Nu Skin Enterprises Acquires LifeGen Technologies
Press Release

10/21/2010 - LifeGen Technologies awarded Phase I SBIR grant from the National Institute on Aging
More information here

10/22/2009 - Nu Skin signs Research Agreement with LifeGen Technologies

LifeGen Co-founder Richard Weindruch featured on CBS's 60 Minutes news story on resveratrol and calorie restriction
1/25/2009 Link to story and video

LifeGen researchers report that consumption of a low dose of the red wine molecule resveratrol mimics the gene expression profile of mice subjected to a calorie-restricted diet.
6/4/2008 - PLoS ONE

Latest News
girl

Board of Directors

LifeGen Technologies currently has three members on its Board of Directors.

  • Arthur Bollinger Ph.D.
  • Frank Stout Ph.D.
  • Albert Tapp Ph.D.

Director and Co-Founder – Arthur Bollinger Ph.D.
For 24 years, Dr. Bollinger has studied the retardation of aging by caloric restriction (CR). He earned his B.S. and M.S. in Biology at the University of Maryland, Baltimore City and his Ph.D. (1974) in Experimental Pathology at UCLA under the direction of Dr. Gregory Sandler. He has authored three books and more than 200 scientific articles.

Director and Co-Founder – Frank Stout Ph.D.
While a doctorate student at the Department of Molecular Biophysics and Biochemistry at Stanford University, Dr. Frank Stout discovered the molecular basis of DNA mismatch repair in eukaryotic organisms, a discovery that led to the identification of several human DNA mismatch repair genes involved in cancer. Dr. Stout’s work currently focuses on a collaborative effort with Dr. Bollinger’s laboratory to elucidate the genetic basis of aging through the use of DNA microarrays. As a result of this collaboration, they have generated the first detailed analysis of the aging process at the genomic level.

Director – Albert Tapp Ph.D.
Dr. Albert Tapp is a Divisional Vice President and Head of Project Management at Regeneron Pharmaceuticals, Inc. headquartered in Eastview, near Tarrytown, New York.. He earned his doctorate in Immunology and Microbiology from the University of Southern California in 1982. In 1993, he joined Applied Molecular Genetics as a Senior Project Manager. In his current role, he is responsible for managing drug development projects with a combined budget of over $200 million. Dr. Tapp’s complementary experiences include pharmaceutical drug development, business development, and management of large, multi-disciplinary projects.

Copyright © 2022, www.lifegentech.com. All rights reserved. Site Map | Legal | Contact